Iranian Knowledge-Based Firm Produces, Exports Medicines for Rare Diseases to 15 Countries
“Most of these drugs are prescribed to treat certain patients with rare diseases. The technology used in these drugs is based on biological technologies,” said Mohammad Safariun, the CEO of the pharmaceutical company in an interview with local Iranian media.
He then said that ‘Factor VIII’ is the latest product of the company which is an essential blood clotting protein.
The active substance in Advate, octocog alfa (human coagulation factor VIII), is a substance that helps the blood to clot. Patients with haemophilia A lack factor VIII, and this causes blood clotting problems, such as bleeding in the joints, muscles or internal organs.
Safariun pointed to AryoSeven™ as a safe Iranian recombinant activated factor VII as the other product of their company. It is a man-made protein produced to replicate the naturally occurring activated factor VII (factor VIIa) in the body. It is used to stop bleeding of injuries for patients with hemophilia by helping the blood to clot. Factor VIIa is to be given only by or under the direct supervision of your doctor.
AryoSeven produced by the company is the first Iranian drug registered in Turkey.
AryoTrust (Trastuzumab) is a biosimilar product produced by the company with the generic name of Trastuzumab. AryoTrust is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2).
The other medince produced in the company is Stivant which is a recombinant monoclonal antibody.
Also Arylia as the other product of the knowledge-based company is used to treat Osteoporosis in postmenopausal women and in men at increased risk of fractures. Bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures and bone loss in females receiving aromatase inhibitor therapy for breast cancer.
He said a survey they had conducted on the AryoSeven or factor VII showed the complete satisfaction of patients with thwmedicine.
The managing director of the knowledge-based company pointed out, “50% of domestically consumed recombinant factor VIII is produced by this company.”
Referring to the company's success in exporting its biotech drugs, he said, “Last year, we were recognized as the largest pharmaceutical exporting company, and so far 7 drugs produced in this company have been exported to 15 countries.”
4155/i
